Cancer immunotherapy by NC410, a LAIR-2 Fc protein blocking human LAIR-collagen interaction
Open accessThe DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Abstract
Collagens are a primary component of the extracellular matrix and are functional ligands for the inhibitory immune receptor leukocyte-associated immunoglobulin-like receptor (LAIR)-1. LAIR-2 is a secreted protein that can act as a decoy receptor by binding collagen with higher affinity than LAIR-1. We propose that collagens promote immune evasion by interacting with LAIR-1 expressed on immune cells, and that LAIR-2 releases LAIR-1-mediated immune suppression. Analysis of public human datasets shows that collagens, LAIR-1 and LAIR-2 have unique and overlapping associations with survival in certain tumors. We designed a dimeric LAIR-2 with a functional IgG1 Fc tail, NC410, and showed that NC410 increases human T cell expansion and effector function in vivo in a mouse xenogeneic-graft versus-host disease model. In humanized mouse tumor models, NC410 reduces tumor growth that is dependent on T cells. Immunohistochemical analysis of human tumors shows that NC410 binds to collagen-rich areas where LAIR-1 + immune cells are localized. Our findings show that NC410 might be a novel strategy for cancer immunotherapy for immune-excluded tumors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Oncology meets immunology: the cancer-immunity cycle.
Chen, D. S., & Mellman, I. (2013) · Immunity · doi:10.1016/j.immuni.2013.07.012 · Cited by 6,929 · cited 1×
“Most human solid tumors exhibit distinct immunological phenotypes being divided into immune-inflamed, immuneexcluded and immune-desert tumors on the basis of immune cell infiltrate and localization (Chen and Mellman, 2013; Binnewies et al., 2018).”
BackgroundUnderstanding the tumor immune microenvironment (TIME) for effective therapy
Binnewies, M., Roberts, E. W., Kersten, K., Chan, V., Fearon, D. F., Merad, M., Coussens, L. M., Gabrilovich, D. I., Ostrand-Rosenberg, S., Hedrick, C. C., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0014-x · Cited by 6,145 · cited 1×
“Most human solid tumors exhibit distinct immunological phenotypes being divided into immune-inflamed, immuneexcluded and immune-desert tumors on the basis of immune cell infiltrate and localization (Chen and Mellman, 2013; Binnewies et al., 2018).”
BackgroundElements of cancer immunity and the cancer–immune set point
Chen, D. S., & Mellman, I. (2017) · Nature · doi:10.1038/nature21349 · Cited by 5,352 · cited 2×
“The immune-excluded phenotype is characterized by the presence of immune cells that cannot penetrate the parenchyma of the tumors but instead are located in the stroma that surrounds the tumor cells (Chen and Mellman, 2017).”
BackgroundSignatures of T cell dysfunction and exclusion predict cancer immunotherapy response
Jiang, P., Gu, S., Pan, D., Fu, J., Sahu, A., Hu, X., Li, Z., Traugh, N., Bu, X., Li, B., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0136-1 · Cited by 5,179 · cited 1×
“These are indications that currently fare poorly with PD-1/PD-L1 immunotherapy (Jiang et al., 2018), and thus NC410 could benefit an entirely new class of cancer patients when used as either a monotherapy or in combination with checkpoint inhibitors.”
BackgroundRemodelling the extracellular matrix in development and disease
Bonnans, C., Chou, J., & Werb, Z. (2014) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3904 · Cited by 4,367 · cited 2×
“Ongoing ECM remodeling ensures tissue integrity and function, with specific collagens being synthesized and degraded in a highly regulated manner (Bonnans et al., 2014).”
BackgroundThe biology and function of fibroblasts in cancer
Kalluri, R. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2016.73 · Cited by 4,366
Matrix Crosslinking Forces Tumor Progression by Enhancing Integrin Signaling
Levental, K. R., Yu, H., Kass, L., Lakins, J. N., Egeblad, M., Erler, J. T., Fong, S. F. T., Csiszar, K., Giaccia, A., Weninger, W., et al. (2009) · Cell · doi:10.1016/j.cell.2009.10.027 · Cited by 4,101
The Extracellular Matrix: Not Just Pretty Fibrils
Hynes, R. O. (2009) · Science · doi:10.1126/science.1176009 · Cited by 3,527 · cited 1×
“The ECM functions not only as a scaffold for tissue organization but also provides critical biochemical and biomechanical cues that instruct cell growth, survival, differentiation and migration and regulate vascular development and immune function (Hynes, 2009).”
BackgroundThe extracellular matrix: A dynamic niche in cancer progression
Lu, P., Weaver, V. M., & Werb, Z. (2012) · Journal of Cell Biology · doi:10.1083/jcb.201102147 · Cited by 3,024
The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy
Havel, J. J., Chowell, D., & Chan, T. A. (2019) · Nature Reviews Cancer · doi:10.1038/s41568-019-0116-x · Cited by 2,286
Immune checkpoint inhibitors: recent progress and potential biomarkers
Darvin, P., Toor, S. M., Sasidharan Nair, V., & Elkord, E. (2018) · Experimental & Molecular Medicine · doi:10.1038/s12276-018-0191-1 · Cited by 2,035 · cited 1×
“However, not all patients show the same degree of response and not all tumors respond to these therapies (Gibney et al., 2016; Darvin et al., 2018).”
BackgroundHow to calculate sample size in animal studies?
Charan, J., & Kantharia, N. D. (2013) · Journal of Pharmacology and Pharmacotherapeutics · doi:10.4103/0976-500x.119726 · Cited by 1,881
Predictive biomarkers for checkpoint inhibitor-based immunotherapy
Gibney, G. T., Weiner, L. M., & Atkins, M. B. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30406-5 · Cited by 1,635 · cited 1×
“However, not all patients show the same degree of response and not all tumors respond to these therapies (Gibney et al., 2016; Darvin et al., 2018).”
BackgroundNaba, A., Clauser, K. R., Hoersch, S., Liu, H., Carr, S. A., & Hynes, R. O. (2012) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m111.014647 · Cited by 1,354
Extracellular Matrix in the Tumor Microenvironment and Its Impact on Cancer Therapy
Henke, E., Nandigama, R., & Ergün, S. (2020) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2019.00160 · Cited by 1,142
Salmon, H., Franciszkiewicz, K., Damotte, D., Dieu-Nosjean, M.-C., Validire, P., Trautmann, A., Mami-Chouaib, F., & Donnadieu, E. (2012) · Journal of Clinical Investigation · doi:10.1172/jci45817 · Cited by 1,138
Immune Escape Mechanisms as a Guide for Cancer Immunotherapy
Beatty, G. L., & Gladney, W. L. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-1860 · Cited by 1,078
The role of collagen in cancer: from bench to bedside
Xu, S., Xu, H., Wang, W., Li, S., Li, H., Li, T., Zhang, W., Yu, X., & Liu, L. (2019) · Journal of Translational Medicine · doi:10.1186/s12967-019-2058-1 · Cited by 735 · cited 1×
“Most tumors overexpress a diverse set of collagens in an abnormal fashion (Nissen et al., 2019; Xu et al., 2019).”
BackgroundSelf-citationCollagen as a double-edged sword in tumor progression
Fang, M., Yuan, J., Peng, C., & Li, Y. (2014) · Tumor Biology · doi:10.1007/s13277-013-1511-7 · Cited by 580 · cited 1×
“Several epithelial tumors including breast, pancreatic, colorectal, ovarian and lung cancer are characterized by a dense ECM where high collagen content correlates with poor prognosis (Fang et al., 2014).”
BackgroundCytokines in Cancer Immunotherapy
Waldmann, T. A. (2018) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a028472 · Cited by 507 · cited 1×
“DOI: https://doi.org/10.7554/eLife.62927 6 of 29 NC410 promotes infiltration and localized activity of T cells in the TME Cytokines and chemokines mediate the host response to tumors by activating and directing the trafficking of immune cells into the TME (Strieter, 2001; Waldmann, 2018).”
BackgroundInfluential
Cited by
Yuan, Z., Li, Y., Zhang, S., Wang, X., Dou, H., Yu, X., Zhang, Z., Yang, S., & Xiao, M. (2023) · Molecular Cancer · doi:10.1186/s12943-023-01744-8 · Cited by 977
“A LAIR-2-Fc recombinant protein also suppresses tumor progression and re-activate anti-tumor immune response [491, 493, 494].”
BackgroundImmune Modulatory Properties of Collagen in Cancer
Rømer, A. M. A., Thorseth, M.-L., & Madsen, D. H. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.791453 · Cited by 231
Single-cell transcriptome profiling of the stepwise progression of head and neck cancer
Choi, J.-H., Lee, B.-S., Jang, J. Y., Lee, Y. S., Kim, H. J., Roh, J., Shin, Y. S., Woo, H. G., & Kim, C.-H. (2023) · Nature Communications · doi:10.1038/s41467-023-36691-x · Cited by 224
Blocking LAIR1 signaling in immune cells inhibits tumor development
Xie, J., Gui, X., Deng, M., Chen, H., Chen, Y., Liu, X., Ku, Z., Tan, L., Huang, R., He, Y., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.996026 · Cited by 36
LILRB3 Supports Immunosuppressive Activity of Myeloid Cells and Tumor Development
Huang, R., Liu, X., Kim, J., Deng, H., Deng, M., Gui, X., Chen, H., Wu, G., Xiong, W., Xie, J., et al. (2024) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-23-0496 · Cited by 24
Metadata
- Authors
- Ramos, M. I. P., Tian, L., de Ruiter, E. J., Song, C., Paucarmayta, A., Singh, A., Elshof, E., Vijver, S. V., Shaik, J., Bosiacki, J., Cusumano, Z., Jensen, C., Willumsen, N., Karsdal, M. A., Liu, L., Langermann, S., Willems, S., Flies, D., & Meyaard, L.
- Venue
- eLife
- Publisher
- eLife Sciences Publications, Ltd
- Published
- 2021-06-14
- Volume
- 10
- ISSN
- 2050-084X (ISSN-L)
- OpenAlex
- W3172306339
- Cited by
- 85
- References
- 20
- FWCI
- 4.54
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.